公开(公告)号：US10988463B2

公开(公告)日：2021-04-27

申请号：US16999295

申请日：2020-08-21

Applicant: Pfizer Inc.

Inventor： Matthew Dowling ,  Dilinie Fernando ,  Kentaro Futatsugi ,  Kim Huard ,  Thomas Victor Magee ,  Brian Raymer ,  Andre Shavnya ,  Aaron Smith ,  Benjamin Thuma ,  Andy Tsai ,  Meihua Tu

IPC: C07D401/14 ,  C07D403/14 ,  A61K31/403 ,  C07D401/04 ,  C07D403/04

Abstract: Provided herein are substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.

公开(公告)号：US10174007B2

公开(公告)日：2019-01-08

申请号：US15729885

申请日：2017-10-11

Applicant: Pfizer Inc.

Inventor： Matthew Dowling ,  Dilinie Fernando ,  Kentaro Futatsugi ,  Kim Huard ,  Thomas Victor Magee ,  Brian Raymer ,  Andre Shavnya ,  Aaron Smith ,  Benjamin Thuma ,  Andy Tsai ,  Meihua Tu

IPC: A61K31/403 ,  C07D403/14 ,  C07D401/04 ,  C07D401/14 ,  C07D403/04

Abstract: Provided herein are substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.

公开(公告)号：US20180037575A1

公开(公告)日：2018-02-08

申请号：US15729885

申请日：2017-10-11

Applicant: Pfizer Inc.

Inventor： Matthew Dowling ,  Dilinie Fernando ,  Kentaro Futatsugi ,  Kim Huard ,  Thomas Victor Magee ,  Brian Raymer ,  Andre Shavnya ,  Aaron Smith ,  Benjamin Thuma ,  Andy Tsai ,  Meihua Tu

IPC: C07D403/14 ,  C07D401/14 ,  C07D401/04 ,  C07D403/04 ,  A61K31/403

CPC classification number: C07D403/14 ,  A61K31/403 ,  C07D401/04 ,  C07D401/14 ,  C07D403/04

Abstract: Provided herein are substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.

公开(公告)号：US09809579B2

公开(公告)日：2017-11-07

申请号：US15381295

申请日：2016-12-16

Applicant: Pfizer Inc.

Inventor： Matthew Dowling ,  Dilinie Fernando ,  Kentaro Futatsugi ,  Kim Huard ,  Thomas Victor Magee ,  Brian Raymer ,  Andre Shavnya ,  Aaron Smith ,  Benjamin Thuma ,  Andy Tsai ,  Meihua Tu

IPC: C07D401/14 ,  C07D403/14 ,  C07D403/04 ,  C07D401/04 ,  A61K31/403

CPC classification number: C07D403/14 ,  A61K31/403 ,  C07D401/04 ,  C07D401/14 ,  C07D403/04

Abstract: Provided herein are substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.

公开(公告)号：US08993586B2

公开(公告)日：2015-03-31

申请号：US14497396

申请日：2014-09-26

Applicant: Pfizer Inc.

Inventor： David A. Griffith ,  Robert L. Dow ,  Scott W. Bagley ,  Aaron Smith

IPC: C07D471/20 ,  A61K31/438

CPC classification number: C07D471/20 ,  C07D519/00

Abstract: The invention provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof; wherein G is R1, R2 and R3 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase enzyme(s) in an animal.

Abstract translation: 本发明提供式（I）化合物或其药学上可接受的盐; 其中G为R 1，R 2和R 3如本文所述; 其药物组合物; 以及其用于治疗通过抑制动物体内的乙酰辅酶A羧化酶调节的疾病，病症或病症的用途。

公开(公告)号：US20150038484A1

公开(公告)日：2015-02-05

申请号：US14518165

申请日：2014-10-20

Applicant: Pfizer Inc.

Inventor： Samit Bhattacharya ,  Kimberly Cameron ,  Matthew Dowling ,  Dilinie Fernando ,  David Ebner ,  Kevin Filipski ,  Daniel Kung ,  Esther Lee ,  Aaron Smith ,  Meihua Tu

IPC: C07D413/12 ,  C07D405/10 ,  C07D403/12 ,  C07D403/04 ,  C07D403/10 ,  C07D405/04 ,  C07D401/10 ,  C07D209/42 ,  C07D405/12

CPC classification number: C07D413/12 ,  A61K31/404 ,  A61K31/416 ,  C07D209/42 ,  C07D231/56 ,  C07D401/04 ,  C07D401/10 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D403/10 ,  C07D403/12 ,  C07D405/04 ,  C07D405/10 ,  C07D405/12 ,  C07D405/14 ,  C07D413/14

Abstract: The present invention relates to indole and indazole compounds of Formula (I) that activate 5′ adenosine monophosphate-activated protein kinase (AMPK). The invention also encompasses pharmaceutical compositions containing these compounds and methods for treating or preventing diseases, conditions, or disorders ameliorated by activation of AMPK.

Abstract translation: 本发明涉及活化5'腺苷单磷酸活化蛋白激酶（AMPK）的式（I）的吲哚和吲唑化合物。 本发明还包括含有这些化合物的药物组合物和用于治疗或预防通过AMPK活化改善的疾病，病症或障碍的方法。

公开(公告)号：US20150025098A1

公开(公告)日：2015-01-22

申请号：US14497396

申请日：2014-09-26

Applicant: PFIZER INC.

Inventor： David A. Griffith ,  Robert L. Dow ,  Scott W. Bagley ,  Aaron Smith

IPC: C07D471/20

CPC classification number: C07D471/20 ,  C07D519/00

Abstract: The invention provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof; wherein G is R1, R2 and R3 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase enzyme(s) in an animal.

Abstract translation: 本发明提供式（I）化合物或其药学上可接受的盐; 其中G为R 1，R 2和R 3如本文所述; 其药物组合物; 以及其用于治疗通过抑制动物体内的乙酰辅酶A羧化酶调节的疾病，病症或病症的用途。

公开(公告)号：US20130267493A1

公开(公告)日：2013-10-10

申请号：US13831588

申请日：2013-03-15

Applicant: PFIZER INC.

Inventor： Samit Bhattacharya ,  Kimberly Cameron ,  Matthew Dowling ,  Dilinie Fernando ,  David Ebner ,  Kevin Filipski ,  Daniel Kung ,  Esther Lee ,  Aaron Smith ,  Meihua Tu

IPC: C07D231/56 ,  C07D209/42 ,  C07D401/10 ,  C07D403/12 ,  C07D413/14 ,  C07D401/14 ,  C07D405/12

CPC classification number: C07D413/12 ,  A61K31/404 ,  A61K31/416 ,  C07D209/42 ,  C07D231/56 ,  C07D401/04 ,  C07D401/10 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D403/10 ,  C07D403/12 ,  C07D405/04 ,  C07D405/10 ,  C07D405/12 ,  C07D405/14 ,  C07D413/14

Abstract: The present invention relates to indole and indazole compounds of Formula (I) that activate 5′ adenosine monophosphate-activated protein kinase (AMPK). The invention also encompasses pharmaceutical compositions containing these compounds and methods for treating or preventing diseases, conditions, or disorders ameliorated by activation of AMPK.

Abstract translation: 本发明涉及活化5'腺苷单磷酸活化蛋白激酶（AMPK）的式（I）的吲哚和吲唑化合物。 本发明还包括含有这些化合物的药物组合物和用于治疗或预防通过AMPK活化改善的疾病，病症或障碍的方法。